Patents by Inventor John J. Masiz
John J. Masiz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108588Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: ApplicationFiled: December 1, 2023Publication date: April 4, 2024Applicants: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Patent number: 11865217Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: GrantFiled: August 10, 2022Date of Patent: January 9, 2024Assignees: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Publication number: 20220387343Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: ApplicationFiled: August 10, 2022Publication date: December 8, 2022Applicants: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Patent number: 11446257Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: GrantFiled: September 25, 2019Date of Patent: September 20, 2022Assignees: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Publication number: 20210259951Abstract: The present invention relates to transmucosal delivery systems, methods and kits that include agents to penetrate the mucus, stratified squamous epithelial layer, and basement membrane, to deliver a vasodilatory agent and active agent to the lamina propria and smooth muscle. The formulation of the present invention further includes having a mucolytic agent for thinning or decreasing viscosity of mucus; a solvent; a proteolytic agent that cleaves or fragments long chain proteins to create cellular spacing of the stratified squamous epithelial layer and/or basement membrane, a vasodilatory agent; and at least one active ingredient. The formulation allows for penetration of the active ingredient at the mucosal surface to the smooth muscle. The active ingredient, once at the smooth muscle, is delivered locally to the tissue or systemically to the blood stream.Type: ApplicationFiled: February 17, 2021Publication date: August 26, 2021Applicants: North Atlantic Holdings LLCInventors: John J. Masiz, Zhen Zhu
-
Patent number: 10751309Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: GrantFiled: January 15, 2016Date of Patent: August 25, 2020Assignee: BioChemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Patent number: 10624867Abstract: The invention provides a topical formulation for treating pain comprising a nonsteroidal anti-inflammatory agent or a Cox-2 inhibitor and a gabapentin family member.Type: GrantFiled: May 9, 2018Date of Patent: April 21, 2020Assignee: Biochemics, Inc.Inventors: Gyula Varadi, Zhen Zhu, John J. Masiz, Stephen G. Carter
-
Publication number: 20200101025Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: ApplicationFiled: September 25, 2019Publication date: April 2, 2020Applicants: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Patent number: 10537536Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: GrantFiled: December 28, 2015Date of Patent: January 21, 2020Assignee: BioChemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Patent number: 10322077Abstract: Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.Type: GrantFiled: January 28, 2016Date of Patent: June 18, 2019Assignee: BioChemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, Diane L. Kozwich, Laura Stephens, John J. Masiz, David H. Donabedian
-
Publication number: 20180325851Abstract: The invention provides a topical formulation for treating pain comprising a nonsteroidal anti-inflammatory agent or a Cox-2 inhibitor and a gabapentin family member.Type: ApplicationFiled: May 9, 2018Publication date: November 15, 2018Inventors: Gyula Varadi, Zhen Zhu, John J. Masiz, Stephen G. Carter
-
Patent number: 9566256Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: GrantFiled: September 22, 2009Date of Patent: February 14, 2017Assignee: Biochemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Publication number: 20160235846Abstract: In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.Type: ApplicationFiled: April 28, 2016Publication date: August 18, 2016Inventors: Stephen G. Carter, John J. Masiz, Laura Stephens, Zhen Zhu, Kanu Patel
-
Publication number: 20160213586Abstract: Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.Type: ApplicationFiled: January 28, 2016Publication date: July 28, 2016Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, Diane L. Kozwich, Laura Stephens, John J. Masiz, David H. Donabedian
-
Publication number: 20160128957Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Publication number: 20160129116Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: ApplicationFiled: December 28, 2015Publication date: May 12, 2016Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Patent number: 9278233Abstract: Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.Type: GrantFiled: December 4, 2009Date of Patent: March 8, 2016Assignee: BioChemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, Diane L. Kozwich, Laura Stephens, John J. Masiz, David H. Donabedian
-
Publication number: 20130245538Abstract: In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.Type: ApplicationFiled: January 3, 2013Publication date: September 19, 2013Applicant: BIOCHEMICS, INC.Inventors: Stephen G. Carter, John J. Masiz, Laura Stephens, Zhen Zhu, Kanu Patel, David H. Donabedian
-
Patent number: 8367122Abstract: In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.Type: GrantFiled: June 11, 2009Date of Patent: February 5, 2013Assignee: BioChemics, Inc.Inventors: Laura Stephens, John J. Masiz, Stephen G. Carter, Zhen Zhu, Kanu Patel
-
Publication number: 20100145256Abstract: Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.Type: ApplicationFiled: December 4, 2009Publication date: June 10, 2010Applicant: BioChemics, Inc.Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, Diane L. Kozwich, Laura Stephens, John J. Masiz, David H. Donabedian